1 Key Insights
2 Executive Summary of Dravet Syndrome
3 SWOT Analysis for Dravet Syndrome
4 Dravet Syndrome Market Overview at a Glance
4.1 Market Share (%) Distribution of Dravet Syndrome in 2017
4.2 Market Share (%) Distribution of Dravet Syndrome in 2030
5 Dravet Syndrome: Disease Background and Overview
5.1 Introduction
5.2 Clinical Features of Dravet Syndrome
5.2.1 Epilepsy
5.2.2 Cognition
5.2.3 Movement disorders
5.2.4 Sudden Death
5.3 Genetics of Dravet Syndrome
5.3.1 Sodium Channel a1 Subunit Gene (SCN1A) and its association with Dravet Syndrome
5.3.2 Functional aspects of voltage gate sodium channel mutations
5.3.3 Detection of SCN1A mutations
5.3.4 Inheritance mode and pattern
5.3.5 Dravet Syndrome without SCN1A Alterations
5.4 Signs and Symptoms of Dravet Syndrome
5.5 Pathophysiology
5.6 Diagnosis of Dravet Syndrome
5.6.1 Differential diagnosis
6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Total Incidence of Dravet Syndrome in 7MM
7 Country Wise-Epidemiology of Dravet Syndrome
8 United States
8.1 Assumptions and Rationale
8.2 Incident Population of Dravet Syndrome
8.3 Mutations associated with Dravet Syndrome
8.3.1 Incidence of Dravet Syndrome by Mutation Class
8.3.2 Incidence of Dravet Syndrome by Mutation Type
8.4 Seizure associated cases of Dravet Syndrome
8.5 Gender-specific Incidence of Dravet Syndrome
8.6 Age-specific Incidence of Dravet Syndrome
9 EU-5
9.1 Assumptions and Rationale
10 Germany
10.1 Incident Population of Dravet Syndrome
10.2 Mutations associated with Dravet Syndrome
10.2.1 Incidence of Dravet Syndrome by Mutation Class
10.2.2 Incidence of Dravet Syndrome by Mutation Type
10.3 Seizure associated cases of Dravet Syndrome
10.4 Gender-specific Incidence of Dravet Syndrome
10.5 Age-specific Incidence of Dravet Syndrome
11 France
11.1 Incident Population of Dravet Syndrome
11.2 Mutations associated with Dravet Syndrome
11.2.1 Incidence of Dravet Syndrome by Mutation Class
11.2.2 Incidence of Dravet Syndrome by Mutation Type
11.3 Seizure associated cases of Dravet Syndrome
11.4 Gender-specific Incidence of Dravet Syndrome
11.5 Age-specific Incidence of Dravet Syndrome
12 Italy
12.1 Incident Population of Dravet Syndrome
12.2 Mutations associated with Dravet Syndrome
12.2.1 Incidence of Dravet Syndrome by Mutation Class
12.2.2 Incidence of Dravet Syndrome by Mutation Type
12.3 Seizure associated cases of Dravet Syndrome
12.4 Gender-specific Incidence of Dravet Syndrome
12.5 Age-specific Incidence of Dravet Syndrome
13 Spain
13.1 Incident Population of Dravet Syndrome
13.2 Mutations associated with Dravet Syndrome
13.2.1 Incidence of Dravet Syndrome by Mutation Class
13.2.2 Incidence of Dravet Syndrome by Mutation Type.
13.3 Seizure associated cases of Dravet Syndrome
13.4 Gender-specific Incidence of Dravet Syndrome
13.5 Age-specific Incidence of Dravet Syndrome
14 United Kingdom
14.1 Incident Population of Dravet Syndrome
14.2 Mutations associated with Dravet Syndrome
14.2.1 Incidence of Dravet Syndrome by Mutation Class
14.2.2 Incidence of Dravet Syndrome by Mutation Type
14.3 Seizure associated cases of Dravet Syndrome
14.4 Gender-specific Incidence of Dravet Syndrome
14.5 Age-specific Incidence of Dravet Syndrome
15 Japan
15.1 Assumptions and Rationale
15.2 Incident Population of Dravet Syndrome
15.3 Mutations associated with Dravet Syndrome
15.3.1 Incidence of Dravet Syndrome by Mutation Class
15.3.2 Incidence of Dravet Syndrome by Mutation Type
15.4 Seizure associated cases of Dravet Syndrome
15.5 Gender-specific Incidence of Dravet Syndrome
15.6 Age-specific Incidence of Dravet Syndrome
16 Treatment of Dravet Syndrome
16.1 Current Treatment Practices
16.1.1 First-Line Therapies: Valproic Acid and Clobazam
16.1.2 Second-Line Therapies
16.1.3 Third Line of Therapies
16.2 Treatment Algorithm
17 Unmet Needs
18 Organizations contributing toward Dravet Syndrome
19 KOL’s Views: Dravet Syndrome
20 Case Studies
20.1 Anesthetic Management of Dravet Syndrome
20.2 Dravet Syndrome and Parkinsonism
21 Marketed Drugs
21.1 Diacomit: Biocodex
21.1.1 Drug Description
21.1.2 Mechanism of Action
21.1.3 Regulatory Milestones
21.1.4 Advantages and Disadvantages
21.1.5 Safety and Efficacy
21.2 Epidiolex: GW Pharmaceuticals
21.2.1 Drug Description
21.2.2 Mechanism of Action
21.2.3 Regulatory Milestones
21.2.4 Advantages and Disadvantages
21.2.5 Safety and Efficacy
22 Emerging Therapies
22.1 ZX-008: Zogenix
22.1.1 Product Description
22.1.2 Other Development Activities
22.1.3 Clinical Development
22.1.4 Safety and Efficacy
22.1 Soticlestat: Ovid Therapeutics
22.1.1 Product Description
22.1.2 Other Development Activities
22.1.3 Clinical Development
22.1.4 Safety and Efficacy
22.2 Ataluren: PTC Therapeutics
22.2.1 Product Description
22.2.2 Clinical Development
23 Dravet Syndrome: Seven Major Market Analysis
23.1 Key Findings
23.2 Total Market Size of Dravet Syndrome in 7MM
24 Market Outlook by Country
24.1 The United States: Market Outlook
24.2 United States Market Size
24.2.1 Total Market Size of Dravet Syndrome
24.2.2 Dravet Syndrome Market Size by Therapies
24.3 EU-5 Countries: Market Outlook
24.4 Germany Market Size
24.4.1 Total Market Size of Dravet Syndrome
24.4.2 Dravet Syndrome Market Size by Therapies
24.5 France Market Size
24.5.1 Total Market Size of Dravet Syndrome
24.5.2 Dravet Syndrome Market Size by Therapies
24.6 Italy Market Size
24.6.1 Total Market Size of Dravet Syndrome
24.6.2 Dravet Syndrome Market Size by Therapies
24.7 Spain Market Size
24.7.1 Total Market Size of Dravet Syndrome
24.7.2 Dravet Syndrome Market Size by Therapies
24.8 The United Kingdom Market Size
24.8.1 Total Market Size of Dravet Syndrome
24.8.2 Dravet Syndrome Market Size by Therapies
24.9 Japan: Market Outlook
24.10 Japan: Market Size
24.10.1 Total Market Size of Dravet Syndrome
24.10.2 Dravet Syndrome Market Size by Therapies
25 Market Drivers
26 Market Barriers
27 Appendix
28 Report Methodology
28.1 Sources Used
29 DelveInsight Capabilities
30 Disclaimer
31 About DelveInsight
Table 1: Genetic background of Dravet syndromeTable 2: Total Incident Population of Dravet Syndrome in 7MM (2017–2030)
Table 3: Incident Population of Dravet Syndrome in the United States (2017–2030)
Table 4: Mutation positive cases of Dravet Syndrome in the United States (2017–2030)
Table 5: Incidence of Dravet Syndrome by Mutation Class in the United States (2017–2030)
Table 6: Incidence of Dravet Syndrome by Mutation Type in the United States (2017–2030)
Table 7: Seizure associated cases of Dravet Syndrome in the United States (2017–2030)
Table 8: Gender-specific Incidence of Dravet Syndrome in the United States (2017–2030)
Table 9: Age-specific Incidence of Dravet Syndrome in the United States (2017–2030)
Table 10: Incident Population of Dravet Syndrome in Germany (2017–2030)
Table 11: Mutation positive cases of Dravet Syndrome in Germany (2017–2030)
Table 12: Incidence of Dravet Syndrome by Mutation Class in Germany (2017–2030)
Table 13: Incidence of Dravet Syndrome by Mutation Type in Germany (2017–2030)
Table 14: Seizure associated cases of Dravet Syndrome in Germany (2017–2030)
Table 15: Gender-specific Incidence of Dravet Syndrome in Germany (2017–2030)
Table 16: Age-specific Incidence of Dravet Syndrome in Germany (2017–2030)
Table 17: Incident Population of Dravet Syndrome in France (2017–2030)
Table 18: Mutation positive cases of Dravet Syndrome in France (2017–2030)
Table 19: Incidence of Dravet Syndrome by Mutation Class in France (2017–2030)
Table 20: Incidence of Dravet Syndrome by Mutation Type in France (2017–2030)
Table 21: Seizure associated cases of Dravet Syndrome in France (2017–2030)
Table 22: Gender-specific Incidence of Dravet Syndrome in France (2017–2030)
Table 23: Age-specific Incidence of Dravet Syndrome in France (2017–2030)
Table 24: Incident Population of Dravet Syndrome in Italy (2017–2030)
Table 25: Mutation positive cases of Dravet Syndrome in Italy (2017–2030)
Table 26: Incidence of Dravet Syndrome by Mutation Class in Italy (2017–2030)
Table 27: Incidence of Dravet Syndrome by Mutation Type in Italy (2017–2030)
Table 28: Seizure associated cases of Dravet Syndrome in Italy (2017–2030)
Table 29: Gender-specific Incidence of Dravet Syndrome in Italy (2017–2030)
Table 30: Age-specific Incidence of Dravet Syndrome in Italy (2017–2030)
Table 31: Incident Population of Dravet Syndrome in Spain (2017–2030)
Table 32: Mutation positive cases of Dravet Syndrome in Spain (2017–2030)
Table 33: Incidence of Dravet Syndrome by Mutation Class in Spain (2017–2030)
Table 34: Incidence of Dravet Syndrome by Mutation Type in Spain (2017–2030)
Table 35: Seizure associated cases of Dravet Syndrome in Spain (2017–2030)
Table 36: Gender-specific Incidence of Dravet Syndrome in Spain (2017–2030)
Table 37: Age-specific Incidence of Dravet Syndrome in Spain (2017–2030)
Table 38: Incident Population of Dravet Syndrome in the United Kingdom (2017–2030)
Table 39: Mutation positive cases of Dravet Syndrome in the United Kingdom (2017–2030)
Table 40: Incidence of Dravet Syndrome by Mutation Class in the United Kingdom (2017–2030)
Table 41: Incidence of Dravet Syndrome by Mutation Type in the United Kingdom (2017–2030)
Table 42: Seizure associated cases of Dravet Syndrome in the United Kingdom (2017–2030)
Table 43: Gender-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)
Table 44: Age-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)
Table 45: Incident Population of Dravet Syndrome in Japan (2017–2030)
Table 46: Mutation positive cases of Dravet Syndrome in Japan (2017–2030)
Table 47: Incidence of Dravet Syndrome by Mutation Class in Japan (2017–2030)
Table 48: Incidence of Dravet Syndrome by Mutation Type in Japan (2017–2030)
Table 49: Seizure associated cases of Dravet Syndrome in Japan (2017–2030)
Table 50: Gender-specific Incidence of Dravet Syndrome in Japan (2017–2030)
Table 51: Age-specific Incidence of Dravet Syndrome in Japan (2017–2030)
Table 52: Organizations contributing towards Dravet Syndrome
Table 53: Seven Major Market Size of Dravet Syndrome in USD Million (2017–2030)
Table 54: 7MM Size of Dravet Syndrome by Therapies in USD Million (2017–2030)
Table 55: The US Market Dravet Syndrome in USD Million (2017–2030)
Table 56: The US Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Table 57: Germany Market of Dravet Syndrome in USD Million (2017–2030)
Table 58: Germany Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Table 59: France Market of Dravet Syndrome in USD Million (2017–2030)
Table 60: France Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Table 61: Italy Market of Dravet Syndrome in USD Million (2017–2030)
Table 62: Italy Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Table 63: Spain Market of Dravet Syndrome in USD Million (2017–2030)
Table 64: Spain Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Table 65: UK Market of Dravet Syndrome in USD Million (2017–2030)
Table 66: UK Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Table 67: Japan Market of Dravet Syndrome in USD Million (2017–2030)
List of Figures
Figure 1: Schematic representation of clinical manifestations of Dravet syndrome
Figure 2: Differential diagnosis of Dravet syndrome in the course of the disease
Figure 3: Total Incident Population of Dravet Syndrome in 7 MM (2017–2030)
Figure 4: Incident Population of Dravet Syndrome in the United States (2017–2030)
Figure 5: Mutation positive cases of Dravet Syndrome in the United States (2017–2030)
Figure 6: Incidence of Dravet Syndrome by Mutation Class in the United States (2017–2030)
Figure 7: Incidence of Dravet Syndrome by Mutation Type in the United States (2017–2030)
Figure 8: Seizure associated cases of Dravet Syndrome in the United States (2017–2030)
Figure 9: Gender-specific Incidence of Dravet Syndrome in the United States (2017–2030)
Figure 10: Age-specific Incidence of Dravet Syndrome in the United States (2017–2030)
Figure 11: Incident Population of Dravet Syndrome in Germany (2017–2030)
Figure 12: Mutation positive cases of Dravet Syndrome in Germany (2017–2030)
Figure 13: Incidence of Dravet Syndrome by Mutation Class in Germany (2017–2030)
Figure 14: Incidence of Dravet Syndrome by Mutation Type in Germany (2017–2030)
Figure 15: Seizure associated cases of Dravet Syndrome in Germany (2017–2030)
Figure 16: Gender-specific Incidence of Dravet Syndrome in Germany (2017–2030)
Figure 17: Age-specific Incidence of Dravet Syndrome in Germany 2017–2030)
Figure 18: Incident Population of Dravet Syndrome in France (2017–2030)
Figure 19: Mutation positive cases of Dravet Syndrome in France (2017–2030)
Figure 20: Incidence of Dravet Syndrome by Mutation Class in France (2017–2030)
Figure 21: Incidence of Dravet Syndrome by Mutation Type in France (2017–2030)
Figure 22: Seizure associated cases of Dravet Syndrome in France (2017–2030)
Figure 23: Gender-specific Incidence of Dravet Syndrome in France (2017–2030)
Figure 24: Age-specific Incidence of Dravet Syndrome in France (2017–2030)
Figure 25: Incident Population of Dravet Syndrome in Italy (2017–2030)
Figure 26: Mutation positive cases of Dravet Syndrome in Italy (2017–2030)
Figure 27: Incidence of Dravet Syndrome by Mutation Class in Italy (2017–2030)
Figure 28: Incidence of Dravet Syndrome by Mutation Type in Italy (2017–2030)
Figure 29: Seizure associated cases of Dravet Syndrome in Italy (2017–2030)
Figure 30: Gender-specific Incidence of Dravet Syndrome in Italy (2017–2030)
Figure 31: Age-specific Incidence of Dravet Syndrome in Italy (2017–2030)
Figure 32: Incident Population of Dravet Syndrome in Spain (2017–2030)
Figure 33: Mutation positive cases of Dravet Syndrome in Spain (2017–2030)
Figure 34: Incidence of Dravet Syndrome by Mutation Class in Spain (2017–2030)
Figure 35: Incidence of Dravet Syndrome by Mutation Type in Spain (2017–2030)
Figure 36: Seizure associated cases of Dravet Syndrome in Spain (2017–2030)
Figure 37: Gender-specific Incidence of Dravet Syndrome in Spain (2017–2030)
Figure 38: Age-specific Incidence of Dravet Syndrome in Spain (2017–2030)
Figure 39: Incident Population of Dravet Syndrome in the United Kingdom (2017–2030)
Figure 40: Mutation positive cases of Dravet Syndrome in the United Kingdom (2017–2030)
Figure 41: Incidence of Dravet Syndrome by Mutation Class in the United Kingdom (2017–2030)
Figure 42: Incidence of Dravet Syndrome by Mutation Type in the United Kingdom (2017–2030)
Figure 43: Seizure associated cases of Dravet Syndrome in the United Kingdom (2017–2030)
Figure 44: Gender-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)
Figure 45: Age-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)
Figure 46: Incident Population of Dravet Syndrome in Japan (2017–2030)
Figure 47: Mutation positive cases of Dravet Syndrome in Japan (2017–2030)
Figure 48: Incidence of Dravet Syndrome by Mutation Class in Japan (2017–2030)
Figure 49: Incidence of Dravet Syndrome by Mutation Type in Japan (2017–2030)
Figure 50: Seizure associated cases of Dravet Syndrome in Japan (2017–2030)
Figure 51: Gender-specific Incidence of Dravet Syndrome in Japan (2017–2030)
Figure 52: Age-specific Incidence of Dravet Syndrome in Japan (2017–2030)
Figure 53: Treatment algorithm of epilepsy in Dravet syndrome.
Figure 54: Unmet Needs for Dravet Syndrome
Figure 55: Seven Major Market Size of Dravet Syndrome in USD Million (2017–2030)
Figure 56: Market Size of Dravet Syndrome in the United States, USD Millions (2017–2030)
Figure 57: The US Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Figure 58: Market Size of Dravet Syndrome in Germany, USD Millions (2017–2030)
Figure 59: Germany Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Figure 60: Market Size of Dravet Syndrome in France, USD Millions (2017–2030)
Figure 61: France Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Figure 62: Market Size of Dravet Syndrome in Italy, USD Millions (2017–2030)
Figure 63: Italy Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Figure 64: Market Size of Dravet Syndrome in Spain, USD Millions (2017–2030)
Figure 65: Spain Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Figure 66: Market Size of Dravet Syndrome in the UK, USD Millions (2017–2030)
Figure 67: The UK Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Figure 68: Market Size of Dravet Syndrome in Japan, USD Millions (2017–2030)
Figure 69: Japan Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Figure 70: Market Drivers of Dravet Syndrome
Figure 71: Market Barriers of Dravet Syndrome
【免責事項】
https://www.marketreport.jp/reports-disclaimer